Pulmonx (LUNG) Competitors

Brainsway (NASDAQ:BWAY) and Pulmonx (NASDAQ:LUNG) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

Is BWAY or LUNG more profitable?

Brainsway has a net margin of 11.60% compared to Pulmonx's net margin of -62.88%. Brainsway's return on equity of 8.97% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainsway	11.60%	8.97%	5.65%
Pulmonx	-62.88%	-69.76%	-36.26%

Does the media prefer BWAY or LUNG?

In the previous week, Brainsway had 20 more articles in the media than Pulmonx. MarketBeat recorded 20 mentions for Brainsway and 0 mentions for Pulmonx. Brainsway's average media sentiment score of 0.72 beat Pulmonx's score of 0.00 indicating that Brainsway is being referred to more favorably in the media.

Company	Overall Sentiment
Brainsway	Positive
Pulmonx	Neutral

Which has more risk and volatility, BWAY or LUNG?

Brainsway has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Pulmonx has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500.

Which has preferable earnings & valuation, BWAY or LUNG?

Brainsway has higher earnings, but lower revenue than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainsway	$41.02M	7.00	$2.92M	$0.26	58.46
Pulmonx	$83.79M	0.82	-$56.39M	-$1.43	-1.18

Do analysts recommend BWAY or LUNG?

Brainsway presently has a consensus target price of $18.00, indicating a potential upside of 18.42%. Pulmonx has a consensus target price of $7.66, indicating a potential upside of 353.51%. Given Pulmonx's higher possible upside, analysts plainly believe Pulmonx is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainsway	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Pulmonx	0 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.56

Do institutionals & insiders believe in BWAY or LUNG?

30.1% of Brainsway shares are owned by institutional investors. Comparatively, 91.0% of Pulmonx shares are owned by institutional investors. 19.0% of Brainsway shares are owned by insiders. Comparatively, 6.8% of Pulmonx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Brainsway beats Pulmonx on 12 of the 16 factors compared between the two stocks.